Danaher Hosts Third Quarter 2022 Earnings Conference Call


“Johnson & Johnson’s expanded presence in the Bay Area confirms our commitment to combining science and technology to deliver transformative healthcare solutions,” said Joaquin Duato, president and CEO of Johnson & Johnson. “On this campus, our talented teams will leverage their diverse experience and expertise to address society’s greatest healthcare challenges to create a better future for patients.”

The R&D focus at the new site covers Janssen’s key therapeutic areas and functions, including emerging sciences and technologies for gene and RNA therapies, new treatments and approaches for retinal and infectious diseases, and data science advanced, including artificial intelligence and machine learning. The co-location of expertise on the site will enable the expansion of the company‘s world-class discovery engine and industry-leading pipeline.

“Our new state-of-the-art science facility in the Bay Area will further strengthen our R&D capabilities and transform how we discover, develop and deliver innovative medicines faster and more efficiently. By integrating drug discovery, data science and digital health, we aim to accelerate the growth of our best-in-class portfolio and deliver better health outcomes to people around the world,” said James. Merson, Ph.D., Site Manager, San Francisco Bay Area Campus and Global Therapeutic Area Leader, Infectious Diseases, Janssen Research & Development, LLC.

The Johnson & Johnson Innovation Center in California has facilitated investments and collaborations to accelerate early-stage healthcare innovation with academic and industry partners across the Bay Area and ecosystem. greater California since 2014. The San Francisco Bay Area campus, along with the Francisco Society’s JLABS @ South San, will continue to enable the Society to build strong relationships with entrepreneurs, scientists, and investors to support and investing in highly differentiated innovations that extend and improve lives everywhere. Additionally, given the convergence of healthcare and technology in the region, the company will place greater emphasis on the Johnson & Johnson Technology organization to enhance its ability to create innovative digital solutions to advance human health.

Building on Johnson & Johnson’s long-standing commitment to using its expertise and resources to reduce the environmental footprint of its operations, the Bay Area hub is designed as a high-performance green campus, strengthening the company’s commitment to be responsible stewards in creating a healthy, more sustainable future. The goal is for the new site to receive Silver Leadership in Energy & Environmental Design (LEED) certification, the world’s most widely used green building rating system.

About Johnson & Johnson
At Johnson & Johnson, we believe that good health is the foundation for vibrant lives, thriving communities and progress. That’s why, for more than 135 years, we’ve focused on the well-being of people at all ages and at every stage of life. Today, as the largest and most widely-located healthcare company in the world, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and make healthy minds, bodies and environments accessible to everyone, everywhere. We unite our hearts, our science and our ingenuity to profoundly change the trajectory of human health. Learn more at www.jnj.com. Follow us on @JNJNews.

About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we are creating a future where illness is a thing of the past. We are the pharmaceutical companies of Johnson & Johnson, working tirelessly to make that future a reality for patients around the world by fighting disease with science, improving access with ingenuity, and healing despair with heart. We focus on the areas of medicine where we can make the biggest difference: cardiovascular, metabolism and retina; Immunology; Infectious diseases and vaccines; neuroscience; Oncology; and pulmonary hypertension. Learn more at www.janssen.com. Follow us on @JanssenGlobal. Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

About Johnson & Johnson Innovation
Johnson & Johnson Innovation LLC works across the pharmaceutical, medical device and consumer healthcare industries to accelerate transformational early-stage solutions by catalyzing the best ideas, wherever they are in the world. We achieve this by leveraging our deep scientific capabilities coupled with a wide range of tools, including custom deal structures, company formation, incubation and start-up services, capital investments and other models. innovative business ideas that aim to meet the diverse needs of entrepreneurs, scientists and emerging businesses. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. Meet our passionate team of science and technology experts and learn how to collaborate with us at www.jnjinnovation.com.

About Johnson & Johnson Technology
Johnson & Johnson Technology solves big problems in healthcare through technology and digital innovation. Just as doctors use scalpels, we use data science, algorithms, artificial intelligence, robotics and other digital solutions to transform the lives of patients. Whether guiding patients through treatment, accelerating vaccine development, or enabling employees to work seamlessly from anywhere, our digital tools infuse our products with novelty, dexterity and ease. Guided by our credo, we unleash the power of technology for good to improve access, equity and sustainability, and shape the future of healthcare as only we can.

Cautions Regarding Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 relating to, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could differ materially from Janssen Research & Development, LLC’s expectations and projections. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents obtained by competitors; challenges inherent in researching and developing new products, including the uncertainty of clinical success and obtaining regulatory approvals; the uncertainty of the commercial success of new and existing products; patent challenges; the impact of patent expirations; the Company’s ability to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, either internally or within the supply chain; product efficacy or safety issues resulting in product recalls or regulatory action; material adverse litigation or governmental action, including related to product liability claims; changes in applicable laws and regulations, including tax laws and global healthcare reforms; trends towards health care cost containment; changes in behavior and spending patterns of purchasers of healthcare products and services; financial instability of international economies and legal systems and sovereign risk; increased surveillance of the health industry by government agencies; the Company’s ability to meet the conditions necessary to effect the separation of the Company’s Consumer Health business in a timely manner or at all; the Company’s ability to successfully separate the Company’s Consumer Health business and realize the expected benefits of the separation; New Consumer Health Company’s ability to succeed as a stand-alone, publicly traded company; and risks related to the impact of the global COVID-19 pandemic, such as the extent and duration of the outbreak, government actions and restrictive measures implemented in response, significant delays and cancellations of medical procedures, supply chain disruptions and other business impacts, or the Company’s ability to execute business continuity plans as a result of the COVID-19 pandemic. A list and additional descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Caution Regarding forward-looking statements”. and “Item 1A. Risk Factors,” as well as in Johnson & Johnson’s subsequent quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or upon request from Johnson & Johnson. Any forward-looking statements made in this release speak only as of the date of this release. Johnson & Johnson does not undertake to update forward-looking statements as a result of new information or future events or developments.

Jake Sargent
+1 732-524-1090
[email protected]

Rachel Jarnagin
+1 415-705-9023
[email protected]

Investor Relations:
Raychel Kruper
+1 732-524-6164
[email protected]


Comments are closed.